Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of SLIT Amikacin in Cystic Fibrosis
NCT06238856Phase 1Completed
- Sponsor
- Insmed Incorporated
- Start
- May 2004
- Primary completion
- Feb 2005
- Modality
- Nanoparticles, Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of amikacin liposome inhalation suspension in cystic fibrosis (CF) and Pseudomonas aeruginosa infection (3 cohorts), sponsored by Insmed Incorporated. Primary endpoint: Number of Participants who Experience a Treatment Emergent Adverse Event. Started May 2004; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT06238856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238856.